

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: AgraFlora Organics International Inc. (the "Issuer").

Trading Symbol: AGRA

Number of Outstanding Listed Securities: 482,922,981

Date: May 21, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On April 3, 2019, the Issuer and Liberty Leaf Holdings Ltd. (CSE: LIB) (OTC: LIBFF) (Frankfurt: HN3P) together, (the "Companies"), announced that, further to the joint news release of September 20, 2018, the Companies have made significant advancement with respect to gaining entry into the medical cannabis market in the European Union and, as such, have formed a joint owned Greek company, AgraLeaf SA ("AgraLeaf"), so as to formally capitalize on the opportunity, as further described in Item 2 below.

On April 4, 2019, the Issuer and Relay Medical Corp. ("Relay") (CSE: RELA, OTCQB: RYMDF, Frankfurt: EIY2) a developer of MedTech innovation, jointly referred to as the "Partners", announced the execution of a binding letter of intent ("LOI") to bring Glow LifeTech Ltd., ("Glow"), the cannabis technology joint venture, public by way of reverse takeover, as further described in Item 2 below.

On April 8, 2019, the Issuer and Relay announced the execution of an asset sale agreement ("Agreement") to transfer a suite of technology assets including the cannabis Smart Consumption System from Relay to Glow, as further described in Item 2 below.

On April 9, 2019, the Issuer and International Cannabis Corp. (CSE: WRLD.U) (FWB: 8K51) (OTC: WLDCF) ("ICC" or "International Cannabis"), have entered into an agreement whereby the Issuer will transfer its portfolio of exotic, native Colombian cannabis genetics to ICC for international marketing and distribution purposes, as further described in Item 2 below.

On April 11, 2019, the Issuer applauds the recently announced rebranding of investee company Empower Clinics Inc. (CSE: EPW) (Frankfurt: 8EC) to better reflect their refocused and refreshed corporate profile and streamlined strategy to become a vertically integrated health and wellness company offering cannabidiol (“CBD”) based therapies, products and treatment options, as further described in Item 2 below.

On April 23, 2019, the Issuer announced the appointments of Mr. Brandon Boddy to the board of directors and of Ms. Jan Urata as corporate secretary, as further described in Item 2 below.

On April 26, 2019, the Issuer announced the progress of the retrofit of the large-scale greenhouse complex in Delta, BC, as further described in Item 2 below.

On April 29, 2019, the Issuer announced the completion of various share issuances, as further described in Item 2 below.

2. Provide a general overview and discussion of the activities of management.

On April 3, 2019, the Companies announced that, further to the joint news release of September 20, 2018, the Companies have made significant advancement with respect to gaining entry into the medical cannabis market in the European Union and, as such, have formed a joint owned Greek company, AgraLeaf so as to formally capitalize on the opportunity. The Issuer and Liberty Leaf will own an equal equity stake in AgraLeaf with specific details regarding the obligations of the Companies to be outlined in a shareholder’s agreement. AgraLeaf has established a team in Greece consisting of personnel with expertise in commercial horticulture, government affairs, legal and finance.

The fertile agricultural regions of Greece combined with relatively low-cost labor and property prices make it a prime locale for large-scale medical cannabis cultivation. In November 2018, Greece issued the first licenses to private companies for growing medicinal cannabis. As a gateway to the European Union, which is home to more than 500 million people, AgraLeaf will thus be granted access to this significant piece of the globalized cannabis market. Recent research reports by Prohibition Partners have estimated that the cannabis market in the EU may represent as much as €123 billion by 2028.

Additional updates and details will be provided in due course as AgraLeaf progresses through the licensing application process.

On April 4, 2019, the Issuer and Relay (CSE: RELA, OTCQB: RYMDF, Frankfurt: EIY2) a developer of MedTech innovation, jointly referred to as the “Partners”, announced the execution of a binding LOI to bring Glow, the cannabis technology joint venture, public by way of reverse takeover. In December 2018 the Partners jointly announced the formation of Glow to identify and develop technologies within the global cannabis sector.

The above-mentioned LOI is to be followed by a formal definitive agreement with Ateba Resources Inc. (“Ateba”) whereby Ateba will acquire all the securities of Glow by way of a share exchange, amalgamation or other transaction, subject to the terms and conditions of the LOI (the “Proposed Transaction”). The definitive agreement will be filed under Ateba's profile on SEDAR at www.sedar.com. Pursuant to the terms of the Proposed Transaction, Ateba will change its name to Glow LifeTech Corp. As a result of the Proposed Transaction, Ateba will continue on with the business of Glow. Glow is responsible for a termination fee of \$100,000 in the event Glow breaches the terms of the LOI. Ateba has no commercial operations, no assets and minimal liabilities.

Under the terms of the LOI, Glow will complete a minimum financing of \$500,000 through the issuance of 2,500,000 common shares prior to the closing of the Proposed Transaction. Additionally, Ateba will complete a 1.555555 for 1 share consolidation prior to the closing of the Proposed Transaction.

Glow is currently owned 63.5% by Relay and 36.5% by the Issuer. With initial funding of at least \$500,000 prior to the closing of the Proposed Transaction, Glow will establish its operational structure with a mandate to find and identify appropriate technology opportunities within the cannabis sector. Glow has commenced initial due diligence on industry related innovative technologies. After the completion of the Proposed Transaction and the contemplated listing, Glow will be positioned to advance and fund its business model with access to public capital markets.

Resulting Capitalization

After completion of the Proposed Transaction, and assuming no further common shares are issued, an aggregate of 15,500,000 common shares in the capital of Ateba (the "Ateba Shares") will be issued and outstanding, with former securityholders of Glow holding 12,500,000 Ateba Shares, representing approximately 80% of the total outstanding Ateba Shares and the original shareholders of Ateba holding 3,000,000 Ateba Shares, representing approximately 20% of the outstanding Ateba Shares. The closing date for the Transaction is expected to be on or around June 30, 2019.

Management and Board of Directors

Upon completion of the Proposed Transaction, the board of directors and management of the resulting issuer will consist of the persons identified below:

W. Clark Kent – President & Chief Executive Officer, Director

Clark is a capital markets professional with extensive experience leading corporate development and finance initiatives in the natural resources, technology and life science industries. For over a decade he has advised emerging companies on strategic planning, finance and recruitment in the North American and international marketplace. Since January 2018 Clark has served as President of MedTech accelerator Relay. Clark began his career with a boutique investment firm where he focused on client relations and marketing.

Chris Hopkins – Chief Financial Officer

Chris has over 25 years of leadership and financial management experience in the capital markets. He has spent most of his career in senior roles with public mining companies, including U.S. Silver, Rio Algom, BHP Billiton, Suncor and several Canadian and international companies. He has a Bachelor of Commerce from the University of Toronto, and a Chartered Accountant designation and MBA from the Schulich School of Business at York University.

Derek Ivany – Director

Mr. Derek Ivany was appointed President and Chief Executive Officer of the Issuer in April 2016 and was instrumental at leading the company away from its resource past to become a large-scale cannabis producer on the world stage. As a public company consultant, Mr. Ivany has worked with numerous publicly traded companies across many different industries. He began his career in investor relations, marketing and corporate development in the oil & gas industry. He transitioned into the junior resource and mining section and most recently to technology and cannabis industries where he has continued to excel. Mr. Ivany continues to be active in both private and public capital markets and is considered an international influencer in the emerging global cannabis industry.

Medhanie Tekeste – Director

Mr. Tekeste is an executive with over 20 years of information systems experience including many years of broad-based management expertise in systems development, implementation and support. He is experienced in strategically and cost effectively utilizing technology to achieve corporate goals. He has extensive global experience in service delivery in the pharmaceutical industry including Quality, Manufacturing and R&D processes. Medhanie also has considerable experience in laboratory quality assurance testing and computer systems validation. Currently, he is the Chief Information Officer at Apotex Inc., where he is responsible for delivery of all end to end IT services globally, including Enterprise Architecture, Cloud and platform services, Service Design, Data Governance, Software Quality Assurance and Security Management, Governance, Program Management and Business Enablement.

Chris Irwin – Director

Chris Irwin practices securities and corporate/commercial law and has been the managing partner of Irwin Lowy LLP since January 2010; prior thereto he was the President of Irwin Professional Corporation from August 2006 to December 2009; and prior thereto he was an associate at Wildeboer Dellelce LLP from January 2004 to July 2006. Mr. Irwin advises a number of public companies, board of directors and independent committees on a variety of issues. Mr. Irwin is a director and/or officer of a number of public companies. Mr. Irwin is a former Director of Trelawney Mining and Exploration Inc., a company acquired by IAMGOLD Corporation in a \$608 million transaction; former Director of Southern Star Resources Inc., which was formerly listed on TSX prior to becoming Gold Eagle Mines Ltd. and being taken over by Goldcorp Inc. in a \$1.5 billion transaction.

Ateba Resources Inc.

Ateba is a reporting issuer in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Quebec and its common shares (the “Ateba Shares”) are not currently listed on any exchange or market. The Company will provide an update on the Proposed Transaction and public listing process in a press release at a later date.

Glow LifeTech Ltd.

Glow is a private company founded by Relay and the Issuer in December 2018 to pursue technology opportunities in the global cannabis sector. The newly formed entity combines Relay’s techno-commercial leadership with the Issuer’s accumulated knowledge, expertise and access to cannabis industries across the sector. Glow will benefit from Relay’s infrastructure, technical leadership and business knowledge for the research, vetting, product development and validation of innovative technologies and the Issuer will support the Company in the pursuit of technology opportunities in scientific validation, diagnostics, health & safety, screening, compliance and quality control/assurance within the cannabis industry.

About Relay Medical Corp.

Relay is an evolving “Integrated MedTech Accelerator” headquartered in Toronto, Canada, acquiring early-stage technologies and inventions, advancing and preparing them for pre-commercial acquisitions in the HealthTech marketplace. By integrating the funding, development and exit process into one organization led and managed by one expert team, Relay is building the capacity to accelerate and transact technologies with high efficiency and grow into a leading engine for MedTech innovation in the global HealthTech marketplace.

For more information visit: www.relaymedical.com

On April 8, 2019, the Issuer and Relay announced the execution of an Agreement to transfer a suite of technology assets including the cannabis Smart Consumption System from Relay to Glow.

The technology assets relate largely to the Smart Consumption System (“SCS”) currently being developed by Relay to provide users and healthcare professionals with a medical grade, connected hardware/software product line to assist with effective management, storage, curation and consumption of cannabis related products. The storage product provides in-home secure, and environmentally controlled storage and guides dispensing and dosing for all cannabis delivery methods.

The system includes advanced management features for patient-caregiver interaction as well as an AI-driven engine, which can provide doctors and the pharmaceutical industry with valuable information on patient responses to cannabis products and to provide cannabis producers with market intelligence and the information to conduct post-market surveillance of their products.

Glow is currently a private company founded by the Partners in December 2018 (See press release dated December 20, 2018) to develop technologies to service the rapidly growing global cannabis sector. On April 4, 2019, the Partners jointly announced the signing of a binding LOI to bring Glow public by way of reverse takeover (“Transaction”).

Under the terms of the agreement, Relay has sold a suite of technology assets relating to the development and licensing of cannabis related medical technologies. In consideration, Glow has issued 6,350,000 shares to Relay resulting in Relay holding approximately 63.5% of Glow prior to the anticipated completion of a private placement and go-public transaction.

On April 9, 2019, the Issuer and ICC have entered into an agreement whereby the Issuer will transfer its portfolio of exotic, native Colombian cannabis genetics to ICC for international marketing and distribution purposes.

In May 2018, the Issuer formed a wholly owned subsidiary, Pure Grow Medicinals S.A.S. (“Pure Grow”), to pursue cannabis cultivation and genetics opportunities in Colombia. Pure Grow has since been working in concert with a Cannabis Cup winner whose strain “Medellin Gold” has received industry accolade and has, since formation, acquired a select library of rare and exotic native cannabis seed varieties from various regions in the country.

The Companies genetics portfolio consists of rare, native cannabis strains from the regions of Valle del Cauca, Cauca, Magdalena and Antioquia in Colombia. Under the agreement, Pure Grow is transferring to International Cannabis a library consisting of 20 unique strains that include both prominent tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) varieties, including highly sought-after strains such as:

- Caucana,
- Purpura,
- Medellin Gold,
- Maroc.

As both the World Health Organization and many countries around the world shift their stance in favour of medical use of CBD-dominant cannabis oils and CBD-derived products, the demand for high-yield CBD strains is expected to increase geometrically.

Under the terms of the agreement, the Issuer will retain the rights to the genetics library for its own uses within North America, and International Cannabis is granted exclusive rights elsewhere globally. In consideration for the transfer of the genetics library, ICC will issue one million common shares to the Issuer. The valuation of the shares will be based upon the five-day VWAP of ICC's common shares for the five trading sessions prior to the announcement of the agreement.

About International Cannabis Corp.

ICC International Cannabis, through its subsidiaries, has operating assets and is developing a world-class platform for cultivation, extraction, formulation and distribution across the globe in the United Kingdom, Denmark, Poland, Switzerland, Germany, Macedonia, Bulgaria, Serbia, Croatia, Greece, Italy, Portugal, Malta, Colombia, Argentina, Australia, South Africa and Lesotho. Learn more about ICC by visiting our website at: <https://intlcannabiscorp.com/>

On April 11, 2019, the Issuer applauds the recently announced rebranding of investee company Empower Clinics Inc. to better reflect their refocused and refreshed corporate profile and streamlined strategy to become a vertically integrated health and wellness company offering CBD based therapies, products and treatment options. As part of the rebranding, Empower will seek shareholder approval for a name change to “CBD Therapeutics Corp.” and it has changed its ticker symbol on the Canadian Securities Exchange to “CBDT”. A new corporate website will also follow.

Empower has been re-positioning its overall strategy to become a vertically integrated health and wellness company that connects to its 120,000 patients using a data driven focus to improve patients' lives with products, technology and health systems. The name change will allow its patients, customers, shareholders, partners, team members and the investment community to have a simple and clear understanding of the Company's focus – a brand that is passionate about CBD based therapies, products and treatment options.

Empower has also launched a new website that is a better reflection of its health & wellness brand, providing users with a more functional and pleasant experience on desktop and mobile devices.

The Issuer will work closely with CBD Therapeutics Corp. to launch new CBD based therapies, product and other health and wellness treatments through CBDT's growing network of clinics.

About Empower Clinics

Empower is a leading owner/operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative uses of medical cannabis. It is expected that Empower's proprietary product line "Sollievo" will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based product options in its clinics, online and at major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.

On April 23, 2019, the Issuer announced the appointment of Mr. Brandon Boddy to the board of directors of the Issuer. Mr. Boddy contributes over 14 years of capital markets experience and has directly raised over \$500 million in the trailing 24 months. Mr. Boddy is a founding director of Auxly Cannabis Group Inc. (formerly Cannabis Wheaton Income Corp.) and is currently a director of Bee Vectoring Technologies International Inc. In addition, Mr. Boddy was a founder of US Cobalt Corp., which was subsequently sold to First Cobalt Corp. for \$149 million in 2018. Mr. Boddy also acts as a corporate advisory consultant for a portfolio of public and private firms, primarily focused on health and wellness, mining and cannabis sectors. Mr. Boddy is actively involved in a variety of philanthropic endeavours. A former NCAA Division One athlete, Mr. Boddy provides opportunities in gold for at-risk youth, by way of his foundation, Clubs for Kids.

The Issuer is also pleased to announce the appointment of Jan Urata as Corporate Secretary of the Issuer. Ms. Urata is the Founder and President of Take It Public Services Inc., since 2011, a highly motivated legal support service for top tier and junior issuers in a variety of industry sectors. She is well versed in taking corporate entities from initial seed capital stage to publicly listed status. Her services include corporate secretarial to regulatory filings to complex transactions while offering corporate sustainability through cost-effective, efficient and timely services. Her business model focuses on performance, attention to detail and results, ensuring success and quality of work, with over 25 years' experience in the industry. The business grew out of her years of experience as a legal secretary/paralegal in top Vancouver law firms. She is also Corporate Secretary of several TSX Venture Exchange issuers.

On April 26, 2019, the Issuer announced the progress of the retrofit of the large-scale greenhouse complex in Delta, BC. (the "Delta Facility"). The retrofit of the 2,200,000 square foot complex has been split into three phases:

- Phase 1 - includes the retrofit of 350,000 square feet of flowering space and 30,000 square feet of post-production facilities, completion scheduled for Q2 2019;
- Phase 2 – consists of an additional 1,450,000 square feet to be completed by Q4 2019; and
- Phase 3 – consists of the remaining 400,000 square feet.

At a recent inspection of the greenhouse, the Issuer's management observed the considerable progress made in the first phase of the retrofit. Preparation of the Delta Facility's growing area including floor repair, electrical wiring, plumbing, installation of walls and security measures is progressing as planned. Installation of a comprehensive security system including renovating secure entrances and exists, and perimeter fencing have begun along with new construction of office spaces and post production areas.

The Delta Facility is operated using a science-based approach to facility design and crop production. There is a focused to optimize every stage of production which ultimately benefits the plants. The greenhouse uses a complex and proprietary energy efficient air exchange, climate and humidity control management system. The ebb and flow watering system includes full irrigation recapture and treatment of water. There is an integrated natural gas-powered power plant providing heat and electricity while utilizing carbon dioxide emissions to benefit the plants. A 1.5-million-gallon hot water storage tank is used to store energy produced during day time for distribute during night. The facility is also designed to maximize natural sunlight balanced with multistage supplemental lighting. It is an impressive facility.

Upon completion of Phase 1 of the retrofit, the Issuer will prepare a detailed video to be submitted to Health Canada as part of the licensing of the Delta Greenhouse Complex. The application for the Delta Greenhouse cultivation license was submitted to Health Canada in Q4 2018. The detailed video submission is the final step for Health Canada for the application and will include details about the growing area including proprietary air filtration, HVAC and watering systems, lighting, post-production facilities and of course the elements that make up the security system for the greenhouse complex.

The Issuer is also pleased to announce the investor and media tour of the Delta Facility has been set for Tuesday, June 25. This date will ensure media, analysts and investors are able to witness the progress made to completing first phase of the conversion. Due to the significant response total registration will be capped at 100. The agenda will include a light lunch, presentation and tours broken into smaller groups.

Delta Greenhouse Complex
2776 – 64th Street, Delta, BC
BBQ, Presentation & Tour
June 25, 2019

The tour is open to Media, Industry Analysts, Shareholders, Investors and other interested parties.

On April 29, 2019, the Issuer announced that, further to its news releases of March 20, 2019 and March 25, 2019, it completed various share issuances to certain parties as detailed out below.

Propagation Services Canada Inc. (“PSC”):

A total of 20,588,235 Shares were issued pursuant to a share purchase agreement with PSC and the shareholders of PSC (the “PSC Shareholders”) dated effective March 19, 2019 (the “Agreement”). Pursuant to the Agreement, the Issuer acquired 10% of the outstanding Class B non-voting participating common shares of PSC (the “PSC Shares”) from the PSC Shareholders for \$14,000,000, payable by the issuance of 20,588,235 Shares of the Issuer at a price of \$0.68 per Share.

Consulting Services:

The Issuer issued an aggregate of 10,000,000 Shares at a deemed price of \$0.51 per Share to key personnel, including related parties, who are assisting with PSC and the Delta Facility which was announced on June 29, 2018.

Letter of Intent:

Pursuant to a letter of intent dated May 22, 2018, the Issuer has issued the first allotment of 1,250,000 Shares to Cornelius Houwelings (the “Consultant”) at a deemed price of \$0.51 per Share. As set out in the LOI, the Issuer agreed to issue an aggregate of 5,000,000 Shares to the Consultant with the remaining 3,750,000 Shares to be issued as follows:

Date of Issuance	No. of Shares
June 25, 2019	1,250,000
September 25, 2019	1,250,000
December 25, 2019	1,250,000
Total:	3,750,000

The Issuer has also agreed to issue the Consultant an additional 5,000,000 Shares upon the achievement of the Delta Facility becoming 100% operational in cannabis.

Supply Agreement:

The Issuer also issued 281,690 Shares at a deemed price of \$0.71 per Share to Vendure Genetics Labs Inc. (the “Supplier”) pursuant to a supply agreement dated December 26, 2018, whereby the Issuer agreed to purchase certain plants, plant matter and related plant-based products from the Supplier for total consideration of \$200,000, payable in Shares.

All Shares issued are subject to a statutory four-month hold period.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Please see Item 2 above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On April 9, 2019, the Issuer announced it has entered into a contractual relationship with International Cannabis. International Cannabis is a non-related party of the Issuer.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Please see Item 2 above.

8. Describe the acquisition of new customers or loss of customers.

N/A.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

N/A.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	20,588,235	20,588,235 common shares issued at \$0.88 per share	Asset Acquisition
Common Shares	10,000,000	10,000,000 common shares issued at \$0.51 per share	Shares for Services
Common Shares	281,690	281,690 common shares issued at \$0.71 per share	Asset Acquisition
Common Shares	1,250,000	1,250,000 common shares issued at \$0.51 per share	Asset Acquisition

15. Provide details of any loans to or by Related Persons.

N/A.

16. Provide details of any changes in directors, officers or committee members.

As mentioned in Item 2 above, on April 23, 2019 the Issuer announced the appointments of Mr. Brandon Boddy to the board of directors and of Ms. Jan Urata as corporate secretary.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Changes in commodity prices, in particular metal prices, and changes in the share performance of other junior mineral exploration companies may affect the Issuer's ability to raise financing.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 21, 2019 .

Derek Ivany
Name of Director or Senior Officer

"Derek Ivany"
Signature

President, CEO & Director
Official Capacity

<i>Issuer Details</i> Name of Issuer	For Month End	Date of Report YY/MM/D
AgraFlora Organics International Inc.	April 2019	19/05/21
Issuer Address Suite 804 – 750 W. Pender Street		
City/Province/Postal Code Vancouver, BC V6C 2T7	Issuer Fax No. (604) 685.6905	Issuer Telephone No. 800.783.6056
Contact Name Derek Ivany	Contact Position President, CEO & Director	Contact Telephone No. 800.783.6056
Contact Email Address derek@agraflora.com	Web Site Address www.agraflora.com	